Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., Chen, R. W., Davies, A., Illidge, T., Huebner, D., Kennedy, D. A., Shustov, A. R. OXFORD UNIV PRESS. 2014
View details for DOI 10.1093/annonc/mdu339.1
View details for Web of Science ID 000346901000272